Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma - Report - MDSpire
Advertisement
Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma
Clinical Report: Phase II Trial Investigating Initial Helicobacter pylori Eradication Treatment for Early-Stage Extragastric MALT Lymphoma
Overview
This phase II trial evaluated the efficacy of frontline Helicobacter pylori eradication (HPE) in patients with early-stage extragastric mucosa-associated lymphoid tissue (MALT) lymphoma. The study found an overall response rate of 65.4%, with 38.5% achieving complete remission.
Background
Helicobacter pylori infection is associated with various forms of lymphoma, including MALT lymphoma. Eradication of H. pylori has been shown to induce remission in gastric MALT lymphoma, and this study explores its potential in extragastric cases.
Data Highlights
Outcome
Result
Complete Remission (CR)
38.5% (10 patients)
Partial Remission (PR)
26.9% (7 patients)
Overall Response Rate (ORR)
65.4% (95% CI, 45.8% to 85.0%)
Median Time to CR
6 months (95% CI, 4.5–7.5 months)
Median Duration of Lymphoma-Free Survival
78.8 months (95% CI, 35.4 to 122.2 months)
Key Findings
Ten patients (38.5%) achieved complete remission (CR) after HPE.
All patients who achieved CR were alive and lymphoma-free at follow-up.
Clinical Implications
The findings suggest that frontline HPE can be an effective treatment option for patients with early-stage extragastric MALT lymphoma. Regular follow-up is essential to monitor for disease progression or remission.
Conclusion
This study supports the use of H. pylori eradication as a viable treatment strategy in early-stage extragastric MALT lymphoma, demonstrating significant response rates and prolonged remission.
